Albireo Pharma, Inc. (ALBO)

NASDAQ: ALBO · IEX Real-Time Price · USD
18.75
-0.61 (-3.15%)
Oct 3, 2022 4:00 PM EDT - Market closed
-3.15%
Market Cap 367.73M
Revenue (ttm) 51.22M
Net Income (ttm) -36.26M
Shares Out 19.61M
EPS (ttm) -1.70
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 152,950
Open 19.50
Previous Close 19.36
Day's Range 18.53 - 19.65
52-Week Range 16.02 - 37.63
Beta 0.93
Analysts Buy
Price Target 55.76 (+197.4%)
Earnings Date Nov 2, 2022

About ALBO

Albireo Pharma, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of novel bile acid modulators to treat orphan pediatric liver diseases and other liver or gastrointestinal diseases and disorders. The company offers Bylvay for the treatment of progressive familial intrahepatic cholestasis, as well as in Phase III clinical trial for treating biliary atresia, alagille syndrome, and rare and life-threatening disorder to children; and Elobixibat for the treatment of chronic constipation and other f... [Read more...]

Industry Biotechnology
CEO Ronald Cooper
Employees 130
Stock Exchange NASDAQ
Ticker Symbol ALBO
Full Company Profile

Financial Performance

In 2021, Albireo Pharma's revenue was $40.58 million, an increase of 388.43% compared to the previous year's $8.31 million. Losses were -$34.03 million, -68.38% less than in 2020.

Financial Statements

Analyst Forecast

According to 13 analysts, the average rating for ALBO stock is "Buy." The 12-month stock price forecast is 55.76, which is an increase of 197.39% from the latest price.

Price Target
$55.76
(197.39% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Albireo Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

BOSTON, Sept. 27, 2022 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a rare disease company developing novel bile acid modulators to treat pediatric and adult liver diseases, today announced ...

6 days ago - GlobeNewsWire

Albireo Pharma (ALBO) Stock Jumps 11%: Will It Continue to Soar?

Albireo Pharma (ALBO) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

1 week ago - Zacks Investment Research

Albireo Announces $115 Million Royalty Monetization Agreement with Sagard

BOSTON, Sept. 22, 2022 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a rare disease company developing novel bile acid modulators to treat pediatric and adult liver diseases, entered into a r...

1 week ago - GlobeNewsWire

Albireo to Participate in Guggenheim Nantucket Therapeutics Conference

BOSTON, Sept. 20, 2022 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a rare disease company developing novel bile acid modulators to treat pediatric and adult liver diseases, today announced ...

1 week ago - GlobeNewsWire

Albireo to Participate in Upcoming Investor Conferences

BOSTON, Sept. 01, 2022 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a rare liver disease company developing novel bile acid modulators to treat pediatric and adult liver diseases, today anno...

1 month ago - GlobeNewsWire

Albireo Pharma (ALBO) Reports Q2 Loss, Misses Revenue Estimates

Albireo Pharma (ALBO) delivered earnings and revenue surprises of -29.11% and 12.89%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

1 month ago - Zacks Investment Research

Is Albireo Pharma (ALBO) Outperforming Other Medical Stocks This Year?

Here is how Albireo Pharma (ALBO) and Arcutis Biotherapeutics, Inc. (ARQT) have performed compared to their sector so far this year.

1 month ago - Zacks Investment Research

Albireo Appoints New Members to Board of Directors

– Habib Dable, Former President and CEO of Acceleron Pharma, and Susan Alesina, Vice President, National Business Development and Alliances at Boston Children's Hospital, bring significant global drug d...

1 month ago - GlobeNewsWire

Albireo to Participate in 2022 Wedbush PacGrow Healthcare Conference

BOSTON, Aug. 03, 2022 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a rare liver disease company developing novel bile acid modulators to treat pediatric and adult liver diseases, today annou...

2 months ago - GlobeNewsWire

Has Albireo Pharma (ALBO) Outpaced Other Medical Stocks This Year?

Here is how Albireo Pharma (ALBO) and GT Biopharma, Inc. (GTBP) have performed compared to their sector so far this year.

2 months ago - Zacks Investment Research

The Lancet Gastroenterology & Hepatology Publishes Data from Albireo's Landmark PEDFIC 1 Study of Bylvay® (odevixibat...

BOSTON, July 06, 2022 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a rare liver disease company developing novel bile acid modulators, today announced that The Lancet Gastroenterology & Hepa...

2 months ago - GlobeNewsWire

Albireo to Present at the William Blair Biotech Focus Conference 2022

BOSTON, June 30, 2022 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a rare liver disease company developing novel bile acid modulators, today announced participation at the William Blair Biot...

3 months ago - GlobeNewsWire

Albireo Presents New Bylvay® (odevixibat) Data at Annual ESPGHAN Congress

BOSTON, June 24, 2022 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a rare liver disease company developing novel bile acid modulators, today announced the presentation of new data at the ann...

3 months ago - GlobeNewsWire

Albireo Announces Presentation of New Data in Pediatric and Adult Liver Diseases

BOSTON, June 23, 2022 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a rare liver disease company developing novel bile acid modulators, today announced the presentation of new data in pediatr...

3 months ago - GlobeNewsWire

Albireo to Present New Data at the 54th Annual Meeting of ESPGHAN

– Four abstracts accepted of Phase 3 data from PEDFIC 1 and PEDFIC 2 trials of Bylvay™ (odevixibat)

3 months ago - GlobeNewsWire

Albireo to Participate at Upcoming Investor Conferences

BOSTON, June 02, 2022 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a rare liver disease company developing novel bile acid modulators, today announced that Ron Cooper, President and Chief Ex...

4 months ago - GlobeNewsWire

Albireo Presented Data in Cholestatic Liver Diseases at Digestive Disease Week (DDW) 2022

– Six abstracts presented highlighting data on Bylvay TM (odevixibat) and effects on pruritus, serum bile acids, growth and sleep parameters

4 months ago - GlobeNewsWire

Albireo to Participate in the H.C. Wainwright Global Investment Conference 2022

BOSTON, May 19, 2022 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a rare liver disease company developing novel bile acid modulators, today announced participation in the H.C. Wainwright Glo...

4 months ago - GlobeNewsWire

Albireo Pharma (ALBO) Reports Q1 Loss, Lags Revenue Estimates

Albireo Pharma (ALBO) delivered earnings and revenue surprises of -8.42% and 12.62%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

4 months ago - Zacks Investment Research

Albireo Reports Q1 2022 Financial Results and Business Update

BOSTON, May 16, 2022 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a rare liver disease company developing novel bile acid modulators, today provided a business update and reported financial ...

4 months ago - GlobeNewsWire

Albireo to Report Q1 2022 Financial Results on May 16

Conference call and webcast to be held at 4:30 pm ET Conference call and webcast to be held at 4:30 pm ET

4 months ago - GlobeNewsWire

Albireo Completes Enrollment in Pivotal Phase 3 ASSERT Study of BylvayTM (odevixibat) in Alagille Syndrome

– Phase 3 ASSERT study on track to report topline data by the end of year

6 months ago - GlobeNewsWire

Albireo Pharma (ALBO) Reports Q4 Loss, Tops Revenue Estimates

Albireo Pharma (ALBO) delivered earnings and revenue surprises of 55.12% and 164.33%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

7 months ago - Zacks Investment Research

Albireo Reports Q4 and Year-End 2021 Financial Results and Business Update

BOSTON, March 01, 2022 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a rare liver disease company developing novel bile acid modulators, today provided a business update and reported financia...

7 months ago - GlobeNewsWire

Is a Surprise Coming for Albireo Pharma (ALBO) This Earnings Season?

Albireo Pharma (ALBO) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

7 months ago - Zacks Investment Research